LifeStance Health Group (NASDAQ:LFST) Trading Up 3.5% on Analyst Upgrade

LifeStance Health Group, Inc. (NASDAQ:LFST) shares rose 3.5% on Thursday after Barclays raised their price target on the stock from $13.00 to $15.00. Barclays currently has an overweight rating on the stock. LifeStance Health Group traded as high as $13.06 and last traded at $13.0660. 699,459 shares were traded during trading, a decline of 80% from the average session volume of 3,475,673 shares. The stock had previously closed at $12.62.

Several other equities analysts also recently commented on LFST. The Goldman Sachs Group began coverage on shares of LifeStance Health Group in a research note on Friday, June 5th. They set a “neutral” rating and a $9.00 price objective for the company. Zacks Research cut LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. KeyCorp boosted their price target on LifeStance Health Group from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Wall Street Zen lowered LifeStance Health Group from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Finally, BTIG Research upped their price target on LifeStance Health Group from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $12.88.

Insider Transactions at LifeStance Health Group

In other LifeStance Health Group news, CTO Vukasin Paunovich sold 42,067 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the transaction, the chief technology officer owned 205,379 shares in the company, valued at approximately $2,643,227.73. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Tpg Gp A, Llc sold 13,643,207 shares of the firm’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $10.62, for a total value of $144,890,858.34. Following the transaction, the insider directly owned 98,101,407 shares of the company’s stock, valued at $1,041,836,942.34. This represents a 12.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 14,671,917 shares of company stock valued at $155,493,415. Company insiders own 3.50% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Assetmark Inc. lifted its position in LifeStance Health Group by 17.0% during the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company’s stock valued at $60,000 after acquiring an additional 1,367 shares during the period. Allworth Financial LP increased its stake in shares of LifeStance Health Group by 7.7% during the second quarter. Allworth Financial LP now owns 26,532 shares of the company’s stock valued at $284,000 after purchasing an additional 1,889 shares in the last quarter. California State Teachers Retirement System increased its stake in shares of LifeStance Health Group by 1.6% during the fourth quarter. California State Teachers Retirement System now owns 125,682 shares of the company’s stock valued at $885,000 after purchasing an additional 1,966 shares in the last quarter. Vident Advisory LLC lifted its holdings in shares of LifeStance Health Group by 12.7% during the second quarter. Vident Advisory LLC now owns 21,732 shares of the company’s stock valued at $112,000 after purchasing an additional 2,447 shares during the last quarter. Finally, Xponance LLC lifted its holdings in shares of LifeStance Health Group by 26.4% during the fourth quarter. Xponance LLC now owns 13,144 shares of the company’s stock valued at $93,000 after purchasing an additional 2,745 shares during the last quarter. 85.50% of the stock is currently owned by institutional investors.

LifeStance Health Group Stock Up 3.5%

The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.18. The company’s fifty day moving average price is $11.60 and its 200-day moving average price is $8.93. The stock has a market capitalization of $5.07 billion, a PE ratio of 100.52 and a beta of 1.22.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of $0.03 by $0.03. LifeStance Health Group had a return on equity of 3.39% and a net margin of 3.19%.The company had revenue of $435.35 million for the quarter, compared to the consensus estimate of $414.58 million. During the same quarter in the prior year, the business posted ($0.01) EPS. The firm’s quarterly revenue was up 26.1% compared to the same quarter last year. Analysts forecast that LifeStance Health Group, Inc. will post 0.16 earnings per share for the current year.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.